Medical Marijuana Inc (MJNA) P/S Ratio
Medical Marijuana Inc (MJNA) has a price-to-sales ratio of 8.64x, placing it in the Expensive range for cannabis stocks. The company has a market cap of $3.28B and TTM revenue of $1.63B. Revenue is growing 0.2% YoY.
P/S Ratio (TTM)
8.64x
EV/Revenue
12.82x
Market Cap
$3.28B
Revenue Growth
+0.2%
Valuation Breakdown
| Metric | Value |
|---|---|
| Stock Price | $9.84 |
| Market Capitalization | $3.28B |
| TTM Revenue | $1.63B |
| Price-to-Sales (TTM) | 8.64x |
| EV/Revenue | 12.82x |
| Revenue Growth (YoY) | +0.2% |
| Gross Margin | -3.9% |
| Sector | MSO |
| Exchange | OTC |
| Valuation Range | Expensive |
Frequently Asked Questions
What is MJNA's current price-to-sales ratio?+
The price-to-sales (P/S) ratio divides Medical Marijuana Inc's market capitalization by its trailing twelve months of revenue. Since many cannabis companies are not yet profitable, P/S is one of the most widely used valuation metrics in the sector. A lower ratio may suggest the stock is undervalued relative to revenue.
How does MJNA's P/S compare to other cannabis stocks?+
P/S ratios in cannabis typically range from 0.5x to 5x depending on growth rate, profitability, and market sentiment. High-growth companies command higher multiples, while mature, lower-growth companies trade at lower multiples. Compare Medical Marijuana Inc to peers in the same sub-sector (MSO, LP, ancillary) for meaningful context.
Is MJNA overvalued or undervalued based on P/S?+
A single metric like P/S cannot definitively determine if Medical Marijuana Inc is over- or undervalued. Consider P/S alongside revenue growth rate, gross margins, cash position, and competitive dynamics. A company growing revenue at 50% YoY may justify a higher P/S than one growing at 5%. Also consider enterprise value-to-revenue (EV/Revenue) which accounts for debt and cash.